Asset Details
Do you wish to reserve the book?
A therapeutic approach to pantothenate kinase associated neurodegeneration
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A therapeutic approach to pantothenate kinase associated neurodegeneration
Do you wish to request the book?
A therapeutic approach to pantothenate kinase associated neurodegeneration
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A therapeutic approach to pantothenate kinase associated neurodegeneration
2018
Overview
Pantothenate kinase (PANK) is a metabolic enzyme that regulates cellular coenzyme A (CoA) levels. There are three human
PANK
genes, and inactivating mutations in
PANK2
lead to pantothenate kinase associated neurodegeneration (PKAN). Here we performed a library screen followed by chemical optimization to produce PZ-2891, an allosteric PANK activator that crosses the blood brain barrier. PZ-2891 occupies the pantothenate pocket and engages the dimer interface to form a PANK•ATP•Mg
2+
•PZ-2891 complex. The binding of PZ-2891 to one protomer locks the opposite protomer in a catalytically active conformation that is refractory to acetyl-CoA inhibition. Oral administration of PZ-2891 increases CoA levels in mouse liver and brain. A knockout mouse model of brain CoA deficiency exhibited weight loss, severe locomotor impairment and early death. Knockout mice on PZ-2891 therapy gain weight, and have improved locomotor activity and life span establishing pantazines as novel therapeutics for the treatment of PKAN.
Mutations in pantotenate kinase (PANK) cause neurodegneration. Here the authors carry out achemical screen and identify a PANK activator that is orally available, crosses the blood brain barrierand show that it effecttive in improving pathology and life span in a mouse model of the disease.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 13/106
/ 49/47
/ 49/98
/ 64/60
/ 82/103
/ 82/80
/ Adenosine Triphosphate - metabolism
/ Animals
/ Dimers
/ Female
/ Humanities and Social Sciences
/ Ligands
/ Liver
/ Locks
/ Male
/ Mutation
/ Pantothenate Kinase-Associated Neurodegeneration - pathology
/ Pantothenate Kinase-Associated Neurodegeneration - therapy
/ Phosphotransferases (Alcohol Group Acceptor) - genetics
/ Rodents
/ Science
